BMS-202

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

BMS-202 is a small-molecule drug PD-L1 inhibitor developed by Bristol-Myers Squibb which displays significant anti-tumor activity against glioblastoma (GBM) cells. In addition, BMS-202 has an inhibitory effect on both PD-L1-expressing cancer cells and activated T cells.

BMS-202 is a small-molecule drug PD-L1 inhibitor developed by Bristol-Myers Squibb which displays significant anti-tumor activity against glioblastoma (GBM) cells. In addition, BMS-202 has an inhibitory effect on both PD-L1-expressing cancer cells and activated T cells.

References

Text derived from https://en.wikipedia.org/w/index.php?oldid=1370308542 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.